DP1 receptor

Target id: 338

Nomenclature: DP1 receptor

Family: Prostanoid receptors

Annotation status:  image of a green circle Annotated and expert reviewed. Please contact us if you can help with updates.  » Email us

Gene and Protein Information
class A G protein-coupled receptor
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 7 359 14q22.1 PTGDR prostaglandin D2 receptor 4
Mouse 7 357 14 B Ptgdr prostaglandin D receptor 15,17
Rat 7 357 15p14 Ptgdr prostaglandin D2 receptor 51
Previous and Unofficial Names
DP1
prostanoid DP receptor-like
PTGDR1
prostaglandin D2 receptor (DP)
Database Links
Specialist databases
GPCRDB pd2r_human (Hs), pd2r_mouse (Mm), pd2r_rat (Rn)
Other databases
ChEMBL Target
Ensembl Gene
Entrez Gene
GeneCards
GenitoUrinary Development Molecular Anatomy Project
HomoloGene
Human Protein Reference Database
InterPro
KEGG Gene
NeXtProt
OMIM
PharmGKB Gene
PhosphoSitePlus
Protein Ontology (PRO)
RefSeq Nucleotide
RefSeq Protein
TreeFam
UniGene Hs.
UniProtKB
Wikipedia
Natural/Endogenous Ligands
PGD2
PGE2
PGF
PGI2
PGJ2
Comments: PGD2 is the principal endogenous agonist
Rank order of potency
PGD2 >> PGE2 > PGF > PGI2, thromboxane A2

Download all structure-activity data for this target as a CSV file

Agonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
[3H]PGD2 Hs Full agonist 7.9 – 9.5 pKd 48,50
pKd 7.9 – 9.5 (Kd 1.3x10-8 – 3x10-10 M) [48,50]
[3H]PGE2 ? Agonist 7.9 – 7.5 pKd
pKd 7.9 – 7.5 (Kd 1.3x10-8 – 3.4x10-8 M)
Δ12-PGJ2 Hs Full agonist 7.0 pKd 50
pKd 7.0 [50]
ZK110841 Hs Full agonist 9.5 pKi 50
pKi 9.5 [50]
L-644,698 Hs Full agonist 9.0 – 9.3 pKi 50-51
pKi 9.0 – 9.3 [50-51]
PGJ2 Hs Full agonist 9.0 pKi 50
pKi 9.0 [50]
BW 245C Hs Full agonist 8.4 – 9.4 pKi 4,50-51
pKi 8.4 – 9.4 [4,50-51]
PGD2 Hs Full agonist 7.8 – 9.2 pKi 4,48,50-51
pKi 7.8 – 9.2 [4,48,50-51]
treprostinil Hs Full agonist 8.4 pKi 47
pKi 8.4 [47]
SQ-27986 Hs Full agonist 8.0 pKi 33
pKi 8.0 [33]
BW 245C Rn Full agonist 7.8 pKi 51
pKi 7.8 [51]
PGD2 Mm Full agonist 7.7 pKi 21
pKi 7.7 [21]
PGD2 Rn Full agonist 7.6 pKi 51
pKi 7.6 [51]
RS 93520 Hs Partial agonist 7.5 pKi 33
pKi 7.5 [33]
L-888,291 Hs Full agonist 7.4 pKi 11
pKi 7.4 [11]
PGE1 Hs Full agonist 7.3 pKi 50
pKi 7.3 [50]
ZK118182 Hs Full agonist 7.3 pKi 33
pKi 7.3 [33]
carbacyclin Hs Full agonist 6.9 pKi 1
pKi 6.9 [1]
L-644,698 Rn Full agonist 6.8 pKi 51
pKi 6.8 [51]
PGE2 Hs Full agonist 6.5 – 7.0 pKi 1,4,50
pKi 6.5 – 7.0 [1,4,50]
15-deoxy-Δ12,14-PGJ2 Hs Full agonist 6.6 pKi 50
pKi 6.6 [50]
BW 245C Mm Full agonist 6.6 pKi 21
pKi 6.6 [21]
iloprost Hs Full agonist 6.0 – 6.6 pKi 1,47,50
pKi 6.0 – 6.6 [1,47,50]
PGF Hs Full agonist 6.1 – 6.4 pKi 1,50
pKi 6.1 – 6.4 [1,50]
U46619 Hs Full agonist 5.4 – 5.9 pKi 1,50
pKi 5.4 – 5.9 [1,50]
butaprost (free acid form) Hs Full agonist 4.9 pKi 1
pKi 4.9 [1]
cloprostenol Hs Full agonist 4.8 pKi 1
pKi 4.8 [1]
View species-specific agonist tables
Agonist Comments
Reference [33] uses human platelet preparations instead of transfected cells.

BW 245C is a useful selective DP1 agonist [12,42,46].
Antagonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
TG6-129 Hs Antagonist 4.8 pKB 9
pKB 4.8 (KB 1.46x10-5 M) [9]
[3H]BWA868C Hs Antagonist 8.8 pKd 34
pKd 8.8 [34]
laropiprant ? Antagonist 10.1 pKi 36
pKi 10.1 [36]
BWA868C Hs Antagonist 8.6 – 9.3 pKi 4,12,50
pKi 8.6 – 9.3 [4,12,50]
S-5751 Hs Antagonist 8.8 pKi 3
pKi 8.8 [3]
ONO-AE3-237 Hs Antagonist 7.7 pKi 16,40-41
pKi 7.7 [16,40-41]
BWA868C Mm Antagonist 6.7 pKi 21
pKi 6.7 [21]
AH6809 Hs Antagonist 5.8 pKi 1
pKi 5.8 [1]
View species-specific antagonist tables
Antagonist Comments
References [3,34] use human platelet preparations instead of transfected cells.

BWA 868C [12,43] is a selective DP1 antagonist with pA2 of 7.8-9.5; S-5751 [3] has a lower selectivity.
Primary Transduction Mechanisms
Transducer Effector/Response
Gs family Adenylate cyclase stimulation
References:  37
Tissue Distribution
Platelets.
Species:  Human
Technique:  Radioligand binding.
References:  34
Colon: mucous-secreting goblet cells.
Species:  Human
Technique:  in situ hybridisation.
References:  49
Eosinophils.
Species:  Human
Technique:  RT-PCR, Southern blotting and in situ hybridisation.
References:  10
Eye: ciliary epithelial cells, longitudinal and circular ciliary muscles, retinal choroid, iris.
Species:  Human
Technique:  Radioligand binding.
References:  34
Airway epithelium.
Species:  Mouse
Technique:  Immunohistochemistry.
References:  22
Brain leptomeninges.
Species:  Mouse
Technique:  In situ hybridization, Northern blot.
References:  29
Arachnoid membrane.
Species:  Mouse
Technique:  Immunohistochemistry.
References:  23
Brain: choroid plexus, leptomeninges.
Spinal cord: ventral horn (motor neurons) > dorsal horn (sensory neurons) of the lumbar spinal cord.
Gastrointestinal tract: stomach, duodenum, ileum, colon (mucous-secreting goblet cells and cuboidal epithelium).
Species:  Rat
Technique:  in situ hybridisation.
References:  51
Expression Datasets

Show »

Log average relative transcript abundance in mouse tissues measured by qPCR from Regard, J.B., Sato, I.T., and Coughlin, S.R. (2008). Anatomical profiling of G protein-coupled receptor expression. Cell, 135(3): 561-71. [PMID:18984166] [Raw data: website]

There should be a chart of expression data here, you may need to enable JavaScript!
Functional Assays
Measurement of Ca2+ levels in HEK 293 cells transfected with the human DP receptor.
Species:  Human
Tissue:  HEK 293 cells.
Response measured:  Increase in Ca2+ concentration.
References:  4
Measurement of cAMP accumulation 9n HEK 293 cells transfected with the rat DP receptor.
Species:  Rat
Tissue:  HEK 293 cells.
Response measured:  Stimulation of cAMP accumulation.
References:  51
Measurement of cAMP levels in human colonic adenocarcinoma cells, LS174T, endogenously expressing the DP receptor.
Species:  Human
Tissue:  LS174T cells.
Response measured:  Stimulation of cAMP accumulation.
References:  49
Measurement of mucin secretion in human colonic adenocarcinoma cells, LS174T, endogenously expressing the DP receptor.
Species:  Human
Tissue:  LS174T cells.
Response measured:  Stimulation of mucin secretion.
References:  49
Measurement of cAMP levels in human platelets endogenously expressing the DP receptor.
Species:  Human
Tissue:  Platelets.
Response measured:  Stimulation of cAMP accumulation.
References:  31
Measurement of adenylate cyclase activity in human platelet membranes.
Species:  Human
Tissue:  Platelets.
Response measured:  Stimulation of AC activity.
References:  2,7,43
Measurement of cAMP levels in HEK 293 cells transfected with the human DP receptor.
Species:  Human
Tissue:  HEK 293 cells.
Response measured:  Stimulation of cAMP accumulation.
References:  4,50-51
Measurement of cAMP levels in a brain astrocytoma cell line transfected with the human DP receptor.
Species:  Human
Tissue:  Glial cells.
Response measured:  Stimulation of cAMP accumulation.
References:  47
Physiological Functions
Inhibition of platelet aggregation.
Species:  Human
Tissue:  Whole blood.
References:  12,20,42
Inhibition of histamine release.
Species:  Rat
Tissue:  Peritoneal mast cells.
References:  5
Relaxation of the myometrium.
Species:  Human
Tissue:  Non-pregnant myometrium.
References:  8,32
Nasal blockage.
Species:  Human
Tissue:  In vivo.
References:  18
Relaxation of smooth muscle.
Species:  Human
Tissue:  Corpus cavernosum.
References:  24
Inhibition of superoxide release from neutrophils.
Species:  Human
Tissue:  Neutrophils.
References:  19
Inhibition of leukotriene B4 and superoxide anion (O2-) release from human neutrophils.
Species:  Human
Tissue:  Neutrophils.
References:  45
Regulation of eosinophil apoptosis.
Species:  Human
Tissue:  Eosinophils.
References:  49
Relaxation of pulmonary venous smooth muscle.
Species:  Human
Tissue:  Pulmonary venous preparations.
References:  44
Relaxation of bronchial smooth muscle.
Species:  Human
Tissue:  Bronchial preparations.
References:  27
Physiological Consequences of Altering Gene Expression
DP receptor knockout OVA-challenged mice exhibit reduced Th2 cytokine levels and lymphocyte accumulation in the lung. In addition, they failed to produce asthmatic responses.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  22
DP receptor knockout mice exhibit reduced nicotinic acid-induced vasodilation.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  6
DP receptor knockout mice infected with Shistosomiasis display impaired retention of Langerhans cells in the epidermis.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  14
DP1 knockout mice do not display prostaglandin D2-induced sleep.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  23
DP1 deletion in mice augments aneurysm formation and the hypertensive response to Angiotensin II and accelerates atherogenesis and thrombogenesis.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  35
DP1 receptor deletion in mice augments intestinal tumour number in a mouse model of intestinal and colon cancer.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  39
DP1 receptor deletion in mice augments vascular leak and enhances tumour growth and vascularity in a mouse model of lung carcinoma.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  25
DP receptor knockout mice exhibit immature dermal mast cells and reduced response in passive cutaneous anaphylaxis, as observed in mice deficient in group III phospholipase A2.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  38
Phenotypes, Alleles and Disease Models Mouse data from MGI

Show »

Allele Composition & genetic background Accession Phenotype Id Phenotype Reference
Galctwi|Ptgdrtm1Sna Galctwi/Galctwi,Ptgdrtm1Sna/Ptgdrtm1Sna
B6.Cg-Galc Ptgdr
MGI:102966  MGI:95636  MP:0002182 abnormal astrocyte morphology PMID: 16624958 
Galctwi|Ptgdrtm1Sna Galctwi/Galctwi,Ptgdrtm1Sna/Ptgdrtm1Sna
B6.Cg-Galc Ptgdr
MGI:102966  MGI:95636  MP:0001393 ataxia PMID: 16624958 
Galctwi|Ptgdrtm1Sna Galctwi/Galctwi,Ptgdrtm1Sna/Ptgdrtm1Sna
B6.Cg-Galc Ptgdr
MGI:102966  MGI:95636  MP:0002083 premature death PMID: 16624958 
Ptgdrtm1Sna Ptgdrtm1Sna/Ptgdrtm1Sna
involves: 129P2/OlaHsd * C57BL/6
MGI:102966  MP:0002405 respiratory system inflammation PMID: 10720327 
Clinically-Relevant Mutations and Pathophysiology
Disease:  Asthma, susceptibility to, 1
Disease Ontology: DOID:2841
OMIM: 607277
Biologically Significant Variants
Type:  Single nucleotide polymorphism
Species:  Human
Description:  TCTG haplotype (T-549C, C-441/T, T-197C and G+1044A) may be linked to an increased risk of post-coital pre-term birth.
References:  13
Type:  Single nucleotide polymorphism
Species:  Human
Description:  The 197T > C variant of the DP receptor may be linked to allergic asthma.
References:  26
Type:  Single nucleotide polymorphisms
Species:  Human
Description:  197T -> C, 441C -> T, and 549T -> C polymorphisms may be linked to asthma.
References:  28,30

References

Show »

1. Abramovitz M, Adam M, Boie Y, Carriere M, Denis D, Godbout C, Lamontagne S, Rochette C, Sawyer N, Tremblay NM, Belley M, Gallant M, Dufresne C, Gareau Y, Ruel R, Juteau H, Labelle M, Ouimet N, Metters KM. (2000) The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogues. Biochim. Biophys. Acta.1483: 285-293. [PMID:10634944]

2. Alvarez R, Eglen RM, Chang LF, Bruno JJ, Artis DR, Kluge AF, Whiting RL. (1991) Stimulation of prostaglandin D2 receptors on human platelets by analogs of prostacyclin. Prostaglandins42: 105-119. [PMID:1775633]

3. Arimura A, Yasui K, Kishino J, Asanuma F, Hasegawa H, Kakudo S, Ohtani M, Arita H. (2001) Prevention of allergic inflammation by a novel prostaglandin receptor antagonist, S-5751. J Pharmacol Exp Ther298: 411-419. [PMID:11454901]

4. Boie Y, Sawyer N, Slipetz DM, Metters KM, Abramovitz M. (1995) Molecular cloning and characterization of the human prostanoid DP receptor. J. Biol. Chem.270: 18910-18916. [PMID:7642548]

5. Chan CL, Jones RL, Lau HYA. (2000) Characterisation of prostanoid receptors mediating inhibition of histamine release from anti-IgE-activated rat peritoneal mast cells. Br. J. Pharmacol.129: 589-597. [PMID:10711359]

6. Cheng K, Wu TJ, Wu KK, Sturino C, Metters K, Gottesdiener K, Wright SD, Wang Z, O'Neill G, Lai E, Waters MG. (2006) Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A103: 6682-6687. [PMID:16617107]

7. Cooper B, Ahern D. (1979) Characterisation of the platelet prostaglandin D2 receptor. J. Clin. Invest.64: 586-590. [PMID:222813]

8. Fernandes B, Crankshaw D. (1996) Functional characterization of the prostanoid DP receptor in human myometrium. Eur. J. Pharmacol.283: 73-81. [PMID:7498323]

9. Ganesh T, Jiang J, Shashidharamurthy R, Dingledine R. (2013) Discovery and characterization of carbamothioylacrylamides as EP2 selective antagonists. ACS Med Chem Lett4 (7): 616-621. [PMID:23914286]

10. Gervais FG, Cruz RP, Chateauneuf A, Gale S, Sawyer N, Nantel F, Metters KM, O'Neill GP. (2001) Selective modulation of chemokinesis, degranulation, and apoptosis in eosinophils through the PGD2 receptors CRTH2 and DP. J Allergy Clin Immunol108: 982-988. [PMID:11742277]

11. Gervais FG, Morello JP, Beaulieu C, Sawyer N, Denis D, Greig G, Malebranche AD, O'Neill GP. (2005) Identification of a potent and selective synthetic agonist at the CRTH2 receptor. Mol Pharmacol67: 1834-1839. [PMID:15755909]

12. Giles H, Leff P, Bolofo ML, Kelly MG, Robertson AD. (1989) The classification of prostaglandin DP-receptors in platelets and vasculature using BW A868C, a novel, selective, and potent competitive antagonist. Br. J. Pharmacol.96: 291-300. [PMID:2924081]

13. Grisaru-Granovsky S, Altarescu G, Finci S, Weintraub A, Tevet A, Samueloff A, Schimmel MS. (2010) Prostanoid DP receptor (PTGDR) variants in mothers with post-coital associated preterm births: preliminary observations. J Perinatol30 (1): 33-7. [PMID:19710676]

14. Hervé M, Angeli V, Pinzar E, Wintjens R, Faveeuw C, Narumiya S, Capron A, Urade Y, Capron M, Riveau G, Trottein F. (2003) Pivotal roles of the parasite PGD2 synthase and of the host D prostanoid receptor 1 in schistosome immune evasion. Eur J Immunol33: 2764-2772. [PMID:14515260]

15. Hirata M, Kakizuka A, Aizawa M, Ushikubi F, Narumiya S. (1994) Molecular characterization of a mouse prostaglandin D receptor and functional expression of the cloned gene. Proc. Natl. Acad. Sci. U.S.A.91: 11192-11196. [PMID:7972033]

16. Hirata T, Narumiya S. (2011) Prostanoid receptors. Chem. Rev.111 (10): 6209-30. [PMID:21819041]

17. Ishikawa TO, Tamai Y, Rochelle JM, Hirata M, Namba T, Sugimoto Y, Ichikawa A, Narumiya S, Taketo MM, Seldin MF. (1996) Mapping of the genes encoding mouse prostaglandin D, E, and F and prostacyclin receptors. Genomics32: 285-288. [PMID:8833158]

18. Johnston SL, Smith S, Harrison J, Ritter W, Howarth PH. (1993) The effect of BAY u 3405, a thromboxane receptor antagonist, on prostaglandin D2-induced nasal blockage. J Allergy Clin Immunol91: 903-909. [PMID:8473679]

19. Kanamori Y, Niwa M, Kohno K, Al-Essa LY, Matsuno H, Kozawa O, Uematsu T. (1997) Migration of neutrophils from blood to tissue: alteration of modulatory effects of prostanoid on superoxide generation in rabbits and humans. Life Sci60: 1407-1417. [PMID:9096262]

20. Keery RJ, Lumley P. (1988) AH6809, a prostaglandin DP-receptor blocking drug on human platelets. Br. J. Pharmacol.94: 745-754. [PMID:2460179]

21. Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya S. (1997) Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br. J. Pharmacol.122: 217-224. [PMID:9313928]

22. Matsuoka T, Hirata M, Tanaka H, Takahashi Y, Murata T, Kabashima K, Sugimoto Y, Kobayashi T, Ushikubi F, Aze Y, Eguchi N, Urade Y, Yoshida N, Kimura K, Mizoguchi A, Honda Y, Nagai H, Narumiya S. (2000) Prostaglandin D2 as a mediator of allergic asthma. Science287: 2013-2017. [PMID:10720327]

23. Mizoguchi A, Eguchi N, Kimura K, Kiyohara Y, Qu WM, Huang ZL, Mochizuki T, Lazarus M, Kobayashi T, Kaneko T, Narumiya S, Urade Y, Hayaishi O. (2001) Dominant localization of prostaglandin D receptors on arachnoid trabecular cells in mouse basal forebrain and their involvement in the regulation of non-rapid eye movement sleep. Proc Natl Acad Sci U S A98: 11674-11679. [PMID:11562489]

24. Moreland RB, Nehra A, Kim NN, Min KS, Albadawi H, Watkins MT, Goldstein I, Traish AM. (2002) Expression of functional prostaglandin D (DP) receptors in human corpus cavernosum smooth muscle. Int J Impot Res14: 446-452. [PMID:12494276]

25. Murata T, Lin MI, Aritake K, Matsumoto S, Narumiya S, Ozaki H, Urade Y, Hori M, Sessa WC. (2008) Role of prostaglandin D2 receptor DP as a suppressor of tumor hyperpermeability and angiogenesis in vivo. Proc. Natl. Acad. Sci. U.S.A.105 (50): 20009-14. [PMID:19060214]

26. Noguchi E, Shibasaki M, Kamioka M, Yokouchi Y, Yamakawa-Kobayashi K, Hamaguchi H, Matsui A, Arinami T. (2002) New polymorphisms of haematopoietic prostaglandin D synthase and human prostanoid DP receptor genes. Clin Exp Allergy32: 93-96. [PMID:12002745]

27. Norel X, Walch L, Labat C, Gascard JP, Dulmet E, Brink C. (1999) Prostanoid receptors involved in the relaxation of human bronchial preparations. Br J Pharmacol126: 867-872. [PMID:10193766]

28. Oguma T, Palmer LJ, Birben E, Sonna LA, Asano K, Lilly CM. (2004) Role of prostanoid DP receptor variants in susceptibility to asthma. N Engl J Med351: 1752-1763. [PMID:15496624]

29. Oida H, Hirata M, Sugimoto Y, Ushikubi F, Ohishi H, Mizuno N, Ichikawa A, Narumiya S. (1997) Expression of messenger RNA for the prostaglandin D receptor in the leptomeninges of the mouse brain. FEBS Lett417: 53-56. [PMID:9395073]

30. Sanz C, Isidoro-García M, Dávila I, Moreno E, Laffond E, Avila C, Lorente F. (2006) Promoter genetic variants of prostanoid DP receptor (PTGDR) gene in patients with asthma. Allergy61: 543-548. [PMID:16629782]

31. Seiler S, Brassard CL, Federici ME. (1990) SQ-27986 inhibition of platelet aggregation is mediated through activation of platelet prostaglandin D2 receptors. Prostaglandins40: 119-130. [PMID:2171039]

32. Senior J, Sangha R, Baxter GS, Marshall K, Clayton JK. (1992) In vitro characterization of prostanoid FP-, DP-, IP- and TP-receptors on the non-pregnant human myometrium. Br J Pharmacol107: 215-221. [PMID:1422574]

33. Sharif NA, Crider JY, Xu SX, Williams GW. (2000) Affinities, selectivities, potencies, and intrinsic activities of natural and synthetic prostanoids using endogenous receptors: focus on DP class prostanoids. J Pharmacol Exp Ther293: 321-328. [PMID:10772998]

34. Sharif NA, Williams GW, Davis TL. (2000) Pharmacology and autoradiography of human DP prostanoid receptors using [(3)H]-BWA868C, a DP receptor-selective antagonist radioligand. Br J Pharmacol131: 1025-1038. [PMID:11082108]

35. Song WL, Stubbe J, Ricciotti E, Alamuddin N, Ibrahim S, Crichton I, Prempeh M, Lawson JA, Wilensky RL, Rasmussen LM et al.. (2012) Niacin and biosynthesis of PGD₂by platelet COX-1 in mice and humans. J. Clin. Invest.122 (4): 1459-68. [PMID:22406532]

36. Sturino CF, O'Neill G, Lachance N, Boyd M, Berthelette C, Labelle M, Li L, Roy B, Scheigetz J, Tsou N et al.. (2007) Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524). J. Med. Chem.50 (4): 794-806. [PMID:17300164]

37. Sugimoto H, Shichijo M, Iino T, Manabe Y, Watanabe A, Shimazaki M, Gantner F, Bacon KB. (2003) An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in vitro. J Pharmacol Exp Ther305: 347-352. [PMID:12649388]

38. Taketomi Y, Ueno N, Kojima T, Sato H, Murase R, Yamamoto K, Tanaka S, Sakanaka M, Nakamura M, Nishito Y et al.. (2013) Mast cell maturation is driven via a group III phospholipase A2-prostaglandin D2-DP1 receptor paracrine axis. Nat. Immunol.14 (6): 554-63. [PMID:23624557]

39. Tippin BL, Kwong AM, Inadomi MJ, Lee OJ, Park JM, Materi AM, Buslon VS, Lin AM, Kudo LC, Karsten SL et al.. (2014) Intestinal tumor suppression in ApcMin/+ mice by prostaglandin D2 receptor PTGDR. Cancer Med3 (4): 1041-51. [PMID:24729479]

40. Torisu K, Kobayashi K, Iwahashi M, Nakai Y, Onoda T, Nagase T, Sugimoto I, Okada Y, Matsumoto R, Nanbu F et al.. (2004) Discovery of a new class of potent, selective, and orally active prostaglandin D2 receptor antagonists. Bioorg. Med. Chem.12 (20): 5361-78. [PMID:15388164]

41. Torres D, Paget C, Fontaine J, Mallevaey T, Matsuoka T, Maruyama T, Narumiya S, Capron M, Gosset P, Faveeuw C et al.. (2008) Prostaglandin D2 inhibits the production of IFN-gamma by invariant NK T cells: consequences in the control of B16 melanoma. J. Immunol.180 (2): 783-92. [PMID:18178816]

42. Town MH, Dournaud P, Gu Y-Z, Schonbrunn A, Mazella J, Tannenbaum GS, Casals-Stenzel J, Schillinger E. (1983) Pharmacological and cardiovascular properties of a hydantoin derivative, BW245C, with high affinity and selectivity for PGD2 receptors. Prostaglandins25: 13-28. [PMID:6302737]

43. Trist DG, Collins BA, Wood J, Kelly MG, Robertson AD. (1989) The antagonism by BW A868C of PGD2 and BW245C activation of human platelet adenylate cyclase. Br. J. Pharmacol.96: 301-306. [PMID:2466517]

44. Walch L, Labat C, Gascard JP, de Montpreville V, Brink C, Norel X. (1999) Prostanoid receptors involved in the relaxation of human pulmonary vessels. Br J Pharmacol126: 859-866. [PMID:10193765]

45. Wheeldon A, Vardey CJ. (1993) Characterization of the inhibitory prostanoid receptors on human neutrophils. Br J Pharmacol108: 1051-1054. [PMID:8387383]

46. Whittle BJ, Moncada S, Mullane K, Vane JR. (1983) Platelet and cardiovascular activity of the hydantoin BW245C, a potent prostaglandin analogue. Prostaglandins25: 205-223. [PMID:6344147]

47. Whittle BJ, Silverstein AM, Mottola DM, Clapp LH. (2012) Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist. Biochem. Pharmacol.84 (1): 68-75. [PMID:22480736]

48. Wilson RJ, Giblin GM, Roomans S, Rhodes SA, Cartwright KA, Shield VJ, Brown J, Wise A, Chowdhury J, Pritchard S, Coote J, Noel LS, Kenakin T, Burns-Kurtis CL, Morrison V, Gray DW, Giles H. (2006) GW627368X ((N-{2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor antagonist. Br J Pharmacol148: 326-339. [PMID:16604093]

49. Wright DH, Ford-Hutchinson AW, Chadee K, Metters KM. (2000) The human prostanoid DP receptor stimulates mucin secretion in LS174T cells. Br J Pharmacol131: 1537-1545. [PMID:11139429]

50. Wright DH, Metters KM, Abramovitz M, Ford-Hutchinson AW. (1998) Characterization of the recombinant human prostaglandin DP-receptor identifies L-644,698 a novel, DP-selective agonist. Br. J. Pharmacol.123: 1317-1324. [PMID:9579725]

51. Wright DH, Nantel F, Metters KM, Ford-Hutchinson AW. (1999) A novel biological role for prostaglandin D2 is suggested by distribution studies of the rat DP prostanoid receptor. Eur J Pharmacol377: 101-115. [PMID:10448933]

How to cite this page

David F. Woodward, Robert L. Jones, Mark Giembycz, Shuh Narumiya, Xavier Norel, Robert A. Coleman, Mark Abramovitz, Richard M. Breyer, Rebecca Hills.
Prostanoid receptors: DP1 receptor. Last modified on 15/08/2016. Accessed on 24/01/2017. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=338.